GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Bijoy Hans Ltd (BOM:524723) » Definitions » EV-to-EBITDA

Bijoy Hans (BOM:524723) EV-to-EBITDA : -45.76 (As of Sep. 27, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Bijoy Hans EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bijoy Hans's enterprise value is ₹53.35 Mil. Bijoy Hans's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was ₹-1.17 Mil. Therefore, Bijoy Hans's EV-to-EBITDA for today is -45.76.

The historical rank and industry rank for Bijoy Hans's EV-to-EBITDA or its related term are showing as below:

BOM:524723' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1503.75   Med: -75.01   Max: 4857.69
Current: -45.76

During the past 13 years, the highest EV-to-EBITDA of Bijoy Hans was 4857.69. The lowest was -1503.75. And the median was -75.01.

BOM:524723's EV-to-EBITDA is not ranked
in the Medical Distribution industry.
Industry Median: 9.1 vs BOM:524723: -45.76

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-27), Bijoy Hans's stock price is ₹23.00. Bijoy Hans's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ₹-0.549. Therefore, Bijoy Hans's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Bijoy Hans EV-to-EBITDA Historical Data

The historical data trend for Bijoy Hans's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bijoy Hans EV-to-EBITDA Chart

Bijoy Hans Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -845.85 -88.18 -30.81 -13.60 -91.17

Bijoy Hans Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.31 -15.88 -20.67 -91.17 -59.18

Competitive Comparison of Bijoy Hans's EV-to-EBITDA

For the Medical Distribution subindustry, Bijoy Hans's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bijoy Hans's EV-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Bijoy Hans's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bijoy Hans's EV-to-EBITDA falls into.



Bijoy Hans EV-to-EBITDA Calculation

Bijoy Hans's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=53.352/-1.166
=-45.76

Bijoy Hans's current Enterprise Value is ₹53.35 Mil.
Bijoy Hans's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-1.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bijoy Hans  (BOM:524723) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Bijoy Hans's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=23.00/-0.549
=At Loss

Bijoy Hans's share price for today is ₹23.00.
Bijoy Hans's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.549.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Bijoy Hans EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bijoy Hans's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bijoy Hans Business Description

Traded in Other Exchanges
N/A
Address
H P Brahmachari Road, Rehabari, Guwahati, AS, IND, 781008
Bijoy Hans Ltd is engaged in the business activity of wholesale pharmaceuticals, medical goods, and cosmetics. The company offers various pharmaceutical formulations such as tablets, capsules, syrups, suspensions, and powders, focusing on antibiotics, cough/cold/allergy, h-1 receptor antagonists, and NSAIDs.

Bijoy Hans Headlines

No Headlines